Trial reportDiabetes, obesity & metabolism2020
Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Trial report in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03724981. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
Open the trial in the graphWho cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.Nature medicine · 2023Trial
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).Diabetes, obesity & metabolism · 2020 · on this mapTrial
- Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.Advances in therapy · 2026Article
- Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis.Patient preference and adherence · 2026Article
- GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.Acta diabetologica · 2024Review
- Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes.Journal of patient-reported outcomes · 2023Article
- Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review.Journal of diabetes science and technology · 2023Review
- Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
- Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.Advances in therapy · 2022Article
- Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions.Diabetes spectrum : a publication of the American Diabetes Association · 2022Article
- Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Review
- Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.Therapeutic advances in endocrinology and metabolism · 2021Review
- Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.Diabetes, obesity & metabolism · 2021Article
- Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).Journal of patient-reported outcomes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
aimWhen selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP-1 receptor agonists. MATERIALS AND
methodsThe PREFER study was an open-label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection-naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time-to-train (TTT) for each device was assessed in a subset.
resultsThere were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001).
conclusionsParticipants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.